questionsmedicales.fr
Composés hétérocycliques
Composés hétéromonocycliques
Pyridines
Composés de pyridinium
Composés de pyridinium : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Composés de pyridinium : Questions médicales les plus fréquentes",
"headline": "Composés de pyridinium : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Composés de pyridinium : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-05",
"dateModified": "2025-03-31",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Composés de pyridinium"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pyridines",
"url": "https://questionsmedicales.fr/mesh/D011725",
"about": {
"@type": "MedicalCondition",
"name": "Pyridines",
"code": {
"@type": "MedicalCode",
"code": "D011725",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Cétylpyridinium",
"alternateName": "Cetylpyridinium",
"url": "https://questionsmedicales.fr/mesh/D002594",
"about": {
"@type": "MedicalCondition",
"name": "Cétylpyridinium",
"code": {
"@type": "MedicalCode",
"code": "D002594",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.232"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Diquat",
"alternateName": "Diquat",
"url": "https://questionsmedicales.fr/mesh/D004178",
"about": {
"@type": "MedicalCondition",
"name": "Diquat",
"code": {
"@type": "MedicalCode",
"code": "D004178",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.352"
}
}
},
{
"@type": "MedicalWebPage",
"name": "1-Méthyl-4-phényl-pyridinium",
"alternateName": "1-Methyl-4-phenylpyridinium",
"url": "https://questionsmedicales.fr/mesh/D015655",
"about": {
"@type": "MedicalCondition",
"name": "1-Méthyl-4-phényl-pyridinium",
"code": {
"@type": "MedicalCode",
"code": "D015655",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.550"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chlorure d'obidoxime",
"alternateName": "Obidoxime Chloride",
"url": "https://questionsmedicales.fr/mesh/D009768",
"about": {
"@type": "MedicalCondition",
"name": "Chlorure d'obidoxime",
"code": {
"@type": "MedicalCode",
"code": "D009768",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.600"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Paraquat",
"alternateName": "Paraquat",
"url": "https://questionsmedicales.fr/mesh/D010269",
"about": {
"@type": "MedicalCondition",
"name": "Paraquat",
"code": {
"@type": "MedicalCode",
"code": "D010269",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.621"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Bromure de pyridostigmine",
"alternateName": "Pyridostigmine Bromide",
"url": "https://questionsmedicales.fr/mesh/D011729",
"about": {
"@type": "MedicalCondition",
"name": "Bromure de pyridostigmine",
"code": {
"@type": "MedicalCode",
"code": "D011729",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.740"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Trimédoxime",
"alternateName": "Trimedoxime",
"url": "https://questionsmedicales.fr/mesh/D014289",
"about": {
"@type": "MedicalCondition",
"name": "Trimédoxime",
"code": {
"@type": "MedicalCode",
"code": "D014289",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.900"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Viologènes",
"alternateName": "Viologens",
"url": "https://questionsmedicales.fr/mesh/D014755",
"about": {
"@type": "MedicalCondition",
"name": "Viologènes",
"code": {
"@type": "MedicalCode",
"code": "D014755",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.925"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Benzyl viologène",
"alternateName": "Benzyl Viologen",
"url": "https://questionsmedicales.fr/mesh/D001594",
"about": {
"@type": "MedicalCondition",
"name": "Benzyl viologène",
"code": {
"@type": "MedicalCode",
"code": "D001594",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.925.100"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Composés de pyridinium",
"alternateName": "Pyridinium Compounds",
"code": {
"@type": "MedicalCode",
"code": "D011726",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sungwoo Hong",
"url": "https://questionsmedicales.fr/author/Sungwoo%20Hong",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST) Daejeon 34141 Korea hongorg@kaist.ac.kr."
}
},
{
"@type": "Person",
"name": "Werner Fudickar",
"url": "https://questionsmedicales.fr/author/Werner%20Fudickar",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Potsdam, Potsdam, Germany."
}
},
{
"@type": "Person",
"name": "Torsten Linker",
"url": "https://questionsmedicales.fr/author/Torsten%20Linker",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Potsdam, Potsdam, Germany."
}
},
{
"@type": "Person",
"name": "Lihua Luo",
"url": "https://questionsmedicales.fr/author/Lihua%20Luo",
"affiliation": {
"@type": "Organization",
"name": "Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. China."
}
},
{
"@type": "Person",
"name": "Rui Sun",
"url": "https://questionsmedicales.fr/author/Rui%20Sun",
"affiliation": {
"@type": "Organization",
"name": "Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A case-control study on immunologic markers of patients with vitiligo.",
"datePublished": "2022-10-14",
"url": "https://questionsmedicales.fr/article/36244264",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.biopha.2022.113785"
}
},
{
"@type": "ScholarlyArticle",
"name": "Case-Control Study of Long COVID, Sapporo, Japan.",
"datePublished": "2023-04-12",
"url": "https://questionsmedicales.fr/article/37044126",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3201/eid2905.221349"
}
},
{
"@type": "ScholarlyArticle",
"name": "Endothelium-biomarkers for postthrombotic syndrome: a case-control study.",
"datePublished": "2023-03-29",
"url": "https://questionsmedicales.fr/article/37016998",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MBC.0000000000001192"
}
},
{
"@type": "ScholarlyArticle",
"name": "Risk Factors for Postoperative Pneumonia: A Case-Control Study.",
"datePublished": "2022-07-08",
"url": "https://questionsmedicales.fr/article/35875004",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2022.913897"
}
},
{
"@type": "ScholarlyArticle",
"name": "Significance of temperature in antimuscarinic toxicity: a case-control study.",
"datePublished": "2022-06-23",
"url": "https://questionsmedicales.fr/article/35735006",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/15563650.2022.2088378"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétéromonocycliques",
"item": "https://questionsmedicales.fr/mesh/D006573"
},
{
"@type": "ListItem",
"position": 4,
"name": "Pyridines",
"item": "https://questionsmedicales.fr/mesh/D011725"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composés de pyridinium",
"item": "https://questionsmedicales.fr/mesh/D011726"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Composés de pyridinium - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Composés de pyridinium",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Composés de pyridinium",
"description": "Comment diagnostiquer une intoxication aux composés de pyridinium ?\nQuels tests sont utilisés pour détecter les composés de pyridinium ?\nQuels symptômes indiquent une exposition aux pyridiniums ?\nLes tests urinaires peuvent-ils détecter les pyridiniums ?\nQuelle est l'importance de l'historique médical dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Case-Control+Studies&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Composés de pyridinium",
"description": "Quels sont les symptômes courants d'une exposition aux pyridiniums ?\nLes composés de pyridinium provoquent-ils des effets neurologiques ?\nY a-t-il des symptômes cutanés associés aux pyridiniums ?\nLes symptômes varient-ils selon le type de pyridinium ?\nComment les symptômes évoluent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Case-Control+Studies&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Composés de pyridinium",
"description": "Quelles mesures préventives peuvent réduire l'exposition aux pyridiniums ?\nLes formations sont-elles nécessaires pour manipuler des pyridiniums ?\nComment stocker les composés de pyridinium en toute sécurité ?\nLes fuites de pyridiniums peuvent-elles être évitées ?\nQuelles sont les recommandations pour les laboratoires ?",
"url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Case-Control+Studies&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Composés de pyridinium",
"description": "Quel est le traitement principal en cas d'intoxication aux pyridiniums ?\nLes soins de soutien sont-ils nécessaires pour les patients exposés ?\nQuels antidotes sont utilisés contre les pyridiniums ?\nLa dialyse est-elle efficace pour éliminer les pyridiniums ?\nComment prévenir les complications lors du traitement ?",
"url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Case-Control+Studies&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Composés de pyridinium",
"description": "Quelles complications peuvent survenir après une exposition aux pyridiniums ?\nLes effets à long terme des pyridiniums sont-ils connus ?\nComment les complications sont-elles gérées ?\nLes complications peuvent-elles être évitées ?\nQuels sont les signes d'alerte pour des complications graves ?",
"url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Case-Control+Studies&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Composés de pyridinium",
"description": "Quels sont les principaux facteurs de risque d'exposition aux pyridiniums ?\nL'âge influence-t-il la sensibilité aux pyridiniums ?\nLes antécédents médicaux augmentent-ils le risque d'intoxication ?\nLes conditions environnementales jouent-elles un rôle ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Case-Control+Studies&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une intoxication aux composés de pyridinium ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique d'exposition et des tests sanguins spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les composés de pyridinium ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analyses chromatographiques et spectrométriques sont couramment utilisées."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une exposition aux pyridiniums ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des nausées, des vomissements et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Les tests urinaires peuvent-ils détecter les pyridiniums ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains tests urinaires peuvent révéler la présence de métabolites pyridiniques."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de l'historique médical dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique médical aide à établir un lien entre les symptômes et l'exposition aux pyridiniums."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants d'une exposition aux pyridiniums ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs abdominales, des vertiges et des troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Les composés de pyridinium provoquent-ils des effets neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent causer des maux de tête, des convulsions et des troubles de la conscience."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés aux pyridiniums ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées et des irritations peuvent survenir après contact avec ces composés."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de pyridinium ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la structure chimique et de la dose."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver sans traitement approprié, nécessitant une intervention rapide."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives peuvent réduire l'exposition aux pyridiniums ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection individuelle lors de la manipulation de ces composés."
}
},
{
"@type": "Question",
"name": "Les formations sont-elles nécessaires pour manipuler des pyridiniums ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des formations sur la sécurité chimique sont essentielles pour les travailleurs exposés."
}
},
{
"@type": "Question",
"name": "Comment stocker les composés de pyridinium en toute sécurité ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les stocker dans des contenants hermétiques et étiquetés, à l'écart des sources de chaleur."
}
},
{
"@type": "Question",
"name": "Les fuites de pyridiniums peuvent-elles être évitées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en vérifiant régulièrement les équipements et en respectant les protocoles de sécurité."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour les laboratoires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les laboratoires doivent suivre des protocoles stricts de manipulation et de stockage des pyridiniums."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal en cas d'intoxication aux pyridiniums ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est la décontamination et l'administration d'antidotes spécifiques."
}
},
{
"@type": "Question",
"name": "Les soins de soutien sont-ils nécessaires pour les patients exposés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des soins de soutien, comme l'hydratation et la surveillance, sont souvent requis."
}
},
{
"@type": "Question",
"name": "Quels antidotes sont utilisés contre les pyridiniums ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antidotes comme l'atropine peuvent être administrés pour contrer les effets toxiques."
}
},
{
"@type": "Question",
"name": "La dialyse est-elle efficace pour éliminer les pyridiniums ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La dialyse peut être envisagée dans les cas graves d'intoxication pour éliminer les toxines."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications lors du traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance étroite et un traitement rapide des symptômes sont essentiels pour prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une exposition aux pyridiniums ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des lésions organiques, des troubles neurologiques et respiratoires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les effets à long terme des pyridiniums sont-ils connus ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets à long terme incluent des troubles cognitifs et des problèmes respiratoires chroniques."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications nécessitent une prise en charge médicale spécialisée et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une intervention rapide et un traitement approprié peuvent réduire le risque de complications."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'alerte pour des complications graves ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des difficultés respiratoires, des convulsions ou une confusion mentale doivent alerter."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque d'exposition aux pyridiniums ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs en chimie, agriculture et industrie sont les plus exposés aux pyridiniums."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il la sensibilité aux pyridiniums ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes enfants et les personnes âgées sont plus sensibles aux effets toxiques."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux augmentent-ils le risque d'intoxication ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies respiratoires ou neurologiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les conditions environnementales jouent-elles un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conditions comme la chaleur ou l'humidité peuvent exacerber les effets des pyridiniums."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines interactions médicamenteuses peuvent augmenter la toxicité des pyridiniums."
}
}
]
}
]
}
Vitiligo is a depigmentation skin disease often coexisting with other autoimmune disorders. The prevalence is 0.5-2 % of the world's population. A combination of genetic, environmental and biochemical...
We conducted a cross-sectional survey among SARS-CoV-2-positive persons and negative controls in Sapporo, Japan, to clarify symptoms of long COVID. We collected responses from 8,018 participants, 3,69...
The postthrombotic syndrome (PTS) is a long-term complication of deep venous thrombosis (DVT). Increase knowledge on the PTS pathophysiology and novel biomarkers are needed in order to predict PTS dev...
A case-control study was conducted. Inclusion criteria were symptomatic and confirmed DVT patients treated with anticoagulants for at least 3 months. Villalta score was performed at the time of inclus...
Thirty two patients and 61 controls were included. PTS patients showed higher levels of CEC (0.56/μl (0.34-1.5) vs. 0.20/μl (0.11-0.77); P = 0.04) and EPC (0.75/μl (0.38-1.52) vs. 0.09/μl (0.05-0.82);...
The formation and early resolution of DVT are characterized by inflammation and endothelial/platelet activation. We have identified possible novel biomarkers such as CEC, EPC and fractalkine for the d...
Postoperative pneumonia is a preventable complication associated with adverse outcomes, that greatly aggravates the medical expenses of patients. The goal of our study is to identify risk factors and ...
A matched 1:1 case-control study, including adult patients who underwent surgery between January 2020 and June 2020, was conducted in the Second Affiliated Hospital of Kunming Medical University in Ch...
Out of 17,190 surgical patients, 264 (1.54%) experienced postoperative pneumonia. Increased age, chronic obstructive pulmonary disease, emergency surgery, postoperative reduced albumin, prolonged vent...
Postoperative pneumonia is associated with severe clinical outcomes. We identified six independent risk factors that can aid in risk stratification and management of patients at risk of postoperative ...
www.chictr.org.cn, identifier: chiCTR2100045986....
Antimuscarinic toxicity can result in temperature dysregulation, but the clinical significance of this is unclear. The objective of this study was to compare peak temperatures between antimuscarinic p...
This was a case-control analysis at two large, urban, academic medical centers from January 1, 2016, through December 31, 2021. We compared peak temperature (...
Fifty-six patients met inclusion criteria of which 23 developed severe outcomes: 16 seizures, 9 cases with hypotension, 5 intubations, and 2 ventricular dysrhythmias. Tmax amongst all patients ranged ...
Maximum temperatures did not differ between patients with and without severe outcomes in the setting of antimuscarinic toxicity, and temperature was poorly predictive of outcomes. Our findings suggest...
Asbestos lung content is regarded as the most reliable tool for causal attribution of malignant mesothelioma (MM) to previous asbestos exposures. However, there is a lack of studies on asbestos burden...
Asbestos lung content has been assessed on formalin-fixed lung fragments using scanning electron microscopy coupled with energy dispersion spectroscopy (SEM-EDS) on individuals deceased from MM (cases...
Asbestos and asbestos bodies (ABs) were found, respectively, in 73.7% and 43.2% of cases and in 28 and 22% of controls; in MM cases the most represented asbestos types were crocidolite and amosite, wh...
The results suggest a correlation between asbestos burden in lungs and MM risk. The different concentration of chrysotile, as well as the different width of asbestos fibers in MM males and females mig...
Psoriasis (PsO) is a chronic inflammatory skin condition, often accompanied by psoriatic arthritis (PsA) and linked to various comorbidities and increased mortality rates. This study aimed to explore ...
Idiopathic intracranial hypertension (IIH) is a condition that mostly affects obese women of childbearing age but has been reported to be temporally related to new diagnoses of anemia. Despite these r...
Consecutive IIH patients were recruited from neuro-ophthalmology clinics and matched by age and sex to consecutive patients attending neuro-ophthalmology clinics with diagnoses other than IIH. Complet...
One hundred twenty-three IIH patients and 113 controls were included in the study. More IIH patients than controls had anemia (22.8%, 28/123 vs 10.6%, 12/113, P = 0.01) with an odds ratio of 2.48 (95%...
Idiopathic intracranial hypertension patients have a higher prevalence of anemia compared with non-IIH neuro-ophthalmology patients. The anemia was mostly mild and may be explained by other factors re...
Adverse drug reactions (ADRs) caused by opioid drugs show individual differences. Our objective was to explore the association between gene polymorphism and ADRs induced by opioid drugs....
Evidence-based medical data analysis was conducted for genes related to ADRs induced by opioid drugs to select target genes. Sixty patients with cancer pain who had ADRs after taking opioid drugs (mor...
Based on a database search and evidence-based medical data, we identified CYP2D6*10, CYP3A5*3, ABCB1, and OPRM1 as target genes for detection. The results of statistical analysis showed no significant...
Polymorphism of ABCB1 (062rs1045642) is related to ADRs caused by oxycodone, and the incidence of ADRs is higher with the allele T. Polymorphism of ABCB1 is expected to become a clinical predictor of ...
The effect of systemic hormone therapy (HT) on dementia risk is unclear. Our aim was to investigate the association between HT and dementia....
This register-based study consists of a nested case-control study and a co-twin control design, which controls for familial confounding, including shared genetics....
Through Danish national registries from 1995 to 2011, we identified: a) 2700 female singletons with incident dementia and 13,492 matched controls; b) 288 female twins with incident dementia and co-twi...
The odds ratio (OR) for the association between systemic HT and dementia was 1.05, 95% CI = [0.93-1.19] in singletons and 2.10, 95% CI = [0.99-4.46] in twins. A statistically significant association w...
Using Danish nationwide registries and controlling for education and for familial factors in a subsample, systemic HT was found to be associated with increased dementia risk if used before 2003, when ...